{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:59:48Z","timestamp":1784696388285,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004263","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio Grande do Sul","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["405128\/2021-5"],"award-info":[{"award-number":["405128\/2021-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.vaccine.2026.128562","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:23:47Z","timestamp":1776252227000},"page":"128562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Effects of candidate vaccines against Zika virus infection: A systematic review of the clinical trials"],"prefix":"10.1016","volume":"81","author":[{"given":"Gabrielle Batista","family":"de Aguiar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meirylanne Gomes","family":"da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Hahn","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Barth","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Aparecida","family":"Bolzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenir Orlandi","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128562_bb0005","author":"World Health Organization"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128562_bb0010","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1056\/NEJMoa0805715","article-title":"Zika virus outbreak on Yap Island, Federated States of Micronesia","volume":"360","author":"Duffy","year":"2009","journal-title":"N Engl J Med."},{"issue":"9","key":"10.1016\/j.vaccine.2026.128562_bb0015","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/jamaneurol.2018.1058","article-title":"Clinical Features of Guillain-Barr\u00e9 Syndrome With vs Without Zika Virus Infection, Puerto Rico, 2016","volume":"75","author":"Dirlikov","year":"2018","journal-title":"JAMA Neurol."},{"issue":"22","key":"10.1016\/j.vaccine.2026.128562_bb0020","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMc1604449","article-title":"Evidence of sexual transmission of zika virus","volume":"374","author":"D\u2019Ortenzio","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128562_bb0025","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0035-9203(52)90042-4","article-title":"Zika virus. I. Isolations and serological specificity","volume":"46","author":"Dick","year":"1952","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128562_bb0030","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1016\/S1473-3099(17)30446-2","article-title":"Zika virus in French Polynesia 2013\u201314: anatomy of a completed outbreak","volume":"18","author":"Musso","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"6283","key":"10.1016\/j.vaccine.2026.128562_bb0035","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1126\/science.aaf5036","article-title":"Zika virus in the americas: early epidemiological and genetic findings","volume":"352","author":"Faria","year":"2016","journal-title":"Science"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2026.128562_bb0040","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1016\/S0264-410X(01)00073-1","article-title":"Rubella eradication","volume":"19","author":"Plotkin","year":"2001","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2026.128562_bb0045","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMsr1604338","article-title":"Zika virus and birth defects\u2014reviewing the evidence for causality","volume":"374","author":"Rasmussen","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128562_bb0050","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1056\/NEJMoa1600651","article-title":"Zika virus associated with microcephaly","volume":"374","author":"Mlakar","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128562_bb0055","article-title":"Adverse fetal and perinatal outcomes associated with zika virus infection during pregnancy: an individual participant data meta-analysis","author":"P\u00e9rez","year":"2025","journal-title":"eClinMed"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128562_bb0060","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1089\/dna.2016.3404","article-title":"Mechanisms of zika virus infection and neuropathogenesis","volume":"35","author":"Olagnier","year":"2016","journal-title":"DNA Cell Biol"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128562_bb0065","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMp1600297","article-title":"Zika virus in the Americas\u2014yet another arbovirus threat","volume":"374","author":"Fauci","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128562_bb0070","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.immuni.2017.02.005","article-title":"Prospects for a zika virus vaccine","volume":"46","author":"Barouch","year":"2017","journal-title":"Immunity"},{"issue":"10120","key":"10.1016\/j.vaccine.2026.128562_bb0075","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(17)33106-9","article-title":"Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials","volume":"391","author":"Modjarrad","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128562_bb0080","doi-asserted-by":"crossref","unstructured":"Stephenson KE, Tan CS, Walsh SR, Hale A, Ansel JL, Kanjilal DG, et al. Safety and immunogenicity of a zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-Centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. Lancet Infect Dis 2020;20(9):1061\u201370. doi:https:\/\/doi.org\/10.1016\/S1473-3099(20)30085-2.","DOI":"10.1016\/S1473-3099(20)30085-2"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128562_bb0085","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/S1473-3099(20)30733-7","article-title":"Safety and immunogenicity of a purified inactivated zika virus vaccine candidate in healthy adults: an observer-blind, randomised, phase 1 trial","volume":"21","author":"Han","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128562_bb0090","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/infdis\/jiac482","article-title":"Persistence of immunogenicity of a purified inactivated zika virus vaccine candidate in healthy adults: 2 years of follow-up compared with natural infection","volume":"227","author":"Acosta","year":"2023","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128562_bb0095","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S1473-3099(23)00192-5","article-title":"Safety and immunogenicity of a purified inactivated zika virus vaccine candidate in adults primed with a japanese encephalitis virus or yellow fever virus vaccine in the USA","volume":"23","author":"Koren","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128562_bb0100","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taac127","article-title":"A randomized, placebo-controlled, blinded phase 1 study investigating a novel inactivated, vero cell-culture derived zika virus vaccine","volume":"31","author":"Wressnigg","year":"2024","journal-title":"J Travel Med"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128562_bb0105","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1708120","article-title":"Safety and immunogenicity of an anti-Zika virus DNA vaccine","volume":"385","author":"Tebas","year":"2021","journal-title":"N Engl J Med"},{"issue":"10120","key":"10.1016\/j.vaccine.2026.128562_bb0110","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(17)33105-7","article-title":"Safety, tolerability, and immunogenicity of two zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials","volume":"391","author":"Gaudinski","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128562_bb0115","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(22)00764-2","article-title":"The safety and immunogenicity of two zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials","volume":"23","author":"Essink","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128562_bb0120","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/M20-5306","article-title":"A double-blind, randomized, placebo-controlled phase 1 study of Ad26.ZIKV.001, an Ad26-vectored anti-Zika virus vaccine","volume":"174","author":"Salisch","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2026.128562_bb0125","series-title":"Zika Virus Research and Development (R&D) Roadmap: September 2021 - Advanced Draft","first-page":"53","author":"World Health Organization","year":"2021"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:08:53Z","timestamp":1777576133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26003701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":25,"alternative-id":["S0264410X26003701"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128562","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of candidate vaccines against Zika virus infection: A systematic review of the clinical trials","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128562","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128562"}}